Phosphodiesterase type 5 inhibition: a support of the left ventricular assist device bridge to transplant.
Semigran
Marc J
MJ
D016027:Heart Transplantation / Q000009:adverse effects; D006352:Heart Ventricles; D006353:Heart-Assist Devices / Q000009:adverse effects; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy / Q000209:etiology; D058986:Phosphodiesterase 5 Inhibitors; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use*; D010879:Piperazines / Q000627:therapeutic use; D011300:Preoperative Care; D011687:Purines / Q000627:therapeutic use; D000068677:Sildenafil Citrate; D013450:Sulfones / Q000627:therapeutic use; D018497:Ventricular Dysfunction, Right / Q000209:etiology / Q000517:prevention & control; D016276:Ventricular Function / Q000187:drug effects
D058986:Phosphodiesterase 5 Inhibitors; D010726:Phosphodiesterase Inhibitors; D010879:Piperazines; D011687:Purines; D013450:Sulfones; D000068677:Sildenafil Citrate